CARCINOMA, NON-SMALL-CELL LUNG

This study tested a drug called lorlatinib in 109 Chinese patients with advanced ALK-positive non-small cell lung cancer whose disease had worsened after previous ALK inhibitor treatment. The goal was to see how many patients' tumors shrank or disappeared. Results help doctors un…

This study tested a combination of two drugs—bevacizumab and a higher dose of icotinib—in 35 adults with advanced non-squamous lung cancer that has a specific genetic mutation (EGFR L858R). The goal was to see if the combo could control the cancer longer than standard treatment. …

This early-phase study tested a new drug (TAK-676) combined with pembrolizumab after radiation therapy in 34 adults with lung, triple-negative breast, or head/neck cancers that had stopped responding to standard treatments. The main goals were to check safety, side effects, and f…

This study tested whether adding a new drug (LY2875358) to the standard treatment erlotinib helps people with advanced non-small cell lung cancer that has spread. All 168 participants first took erlotinib alone for 8 weeks. Those whose cancer did not worsen were then randomly ass…

This study tested whether adding experimental drugs (boserolimab, MK-4830, or MK-0482) to the immunotherapy pembrolizumab could shrink tumors or slow cancer growth in 128 adults with advanced non-small cell lung cancer (NSCLC) who had already received anti-PD-(L)1 therapy. The ma…

This study looked at how safe and effective the drug Tagrisso (osimertinib) is for people with a certain type of advanced lung cancer in everyday medical practice. Over 900 patients in Korea took part, and researchers tracked side effects and how well the drug controlled the canc…

This study tested whether adding an experimental drug (MK-4830 or MK-0482) to the standard immunotherapy pembrolizumab could shrink tumors or slow cancer growth in people with advanced non-small cell lung cancer that has a specific marker (PD-L1 positive). 102 people who had not …

This study tested a new immunotherapy drug, cemiplimab, against standard chemotherapy in 712 people with advanced non-small cell lung cancer that has a specific marker (PD-L1). The goal was to see if cemiplimab helps people live longer or keeps the cancer from growing longer than…

This early-phase study tested a new drug called boserolimab (MK-5890), either alone or combined with pembrolizumab, in 182 adults with advanced solid tumors (including lung and triple-negative breast cancers). The main goal was to check safety and how the drug moves through the b…

This study looked at whether giving palliative radiation to 2 to 5 tumor sites before starting standard immunotherapy and chemotherapy can help people with advanced non-small cell lung cancer. Fifty adults with stage IV cancer and low PD-L1 levels took part. The goal was to see i…

This study looked at the safety of combining two immunotherapy drugs (IMJUDO and IMFINZI) with standard chemotherapy for people with advanced or recurrent non-small cell lung cancer that cannot be removed by surgery. Researchers tracked side effects in 296 patients treated in eve…

This study tested a drug called cabozantinib, given alone or with another drug called erlotinib, in 92 adults with advanced non-small cell lung cancer. Participants had already tried erlotinib and their cancer had gotten worse. The goal was to find a safe dose and see if the comb…

This study tested two experimental drugs, BI 754111 and BI 754091, that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found the safest dose, and…

This study tested a combination of two drugs, atezolizumab and cabozantinib, against a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that had worsened after prior treatments. The goal was to see if the combination helped people live longer. …

This study tested a combination of two targeted drugs, dabrafenib and trametinib, in 40 Chinese adults with a specific type of advanced lung cancer (BRAF V600E mutation-positive NSCLC). The goal was to see if the drugs could shrink tumors. Participants took the drugs until their …

This study tested a combination of two drugs, SHR-1210 and apatinib, in 210 people with advanced non-small cell lung cancer that had stopped responding to earlier treatments. The goal was to see if the combination was safe and could shrink tumors. Participants received the drugs …

This study tested a combination of the immunotherapy drug durvalumab with two chemotherapy drugs (doxorubicin and ifosfamide) in 16 people with a rare and aggressive type of lung cancer called pulmonary sarcomatoid carcinoma. The goal was to see if the combo could shrink tumors a…

This early-phase study tested whether giving patients their own specially grown natural killer (NK) cells, combined with the drug bortezomib, is safe for people with advanced solid tumors or leukemia that no longer respond to standard treatments. 35 adults received increasing dos…

This early-stage study tested a new drug called SGN-B6A in 6 Chinese adults with advanced solid tumors (lung, head/neck, esophageal, or stomach cancers) that had stopped responding to standard treatments. The main goal was to check the drug's safety and side effects, and to see h…

This study tested a new method called the mass response biomarker to see if it can predict how well a cancer patient will respond to specific treatments. Researchers collected tumor cells from 72 adults with various cancers using fluid samples or tissue biopsies. The goal was to …